RSS   Newsletter   Contact   Advertise with us

Nivalis Therapeutics adds Cynthia Smith to board

Staff Writer | Boulder, Co., USA | November 7, 2016
Nivalis TherapeuticsNovember 7, 2016, Boulder, Co., USA - Nivalis Therapeutics, a clinical stage pharmaceutical company, announced that Cynthia Smith, chief commercial officer of ZS Pharma, a subsidiary of AstraZeneca, has been appointed to the company’s board.
Ms. Smith has more than 20 years of broad leadership experience within the healthcare industry.

Since 2013, Ms. Smith has served as chief commercial officer and a member of the executive team of ZS Pharma, where she led efforts to transition the company from the development stage to a commercial enterprise.

ZS Pharma was acquired by AstraZeneca in 2015.

Prior to joining ZS Pharma, Ms. Smith served as vice president, market access and commercial development at Affymax, Inc.

She also held various senior leadership positions in market access, corporate strategy, government relations and external affairs at Merck & Co.

Before beginning her career in the biopharmaceutical industry, Ms. Smith served as a healthcare policy analyst in the White House Office of Management and Budget.

Ms. Smith earned her M.B.A. from the Wharton School of the University of Pennsylvania, and a M.S. in public policy from the Eagleton Institute of Politics at Rutgers University. She received a B.A. from the University of North Carolina at Chapel Hill.